百济神州2025年净利14.22亿元，同比扭亏

Core Viewpoint - BeiGene reported a significant increase in revenue and profitability for the fiscal year 2025, driven by product sales growth and improved operational efficiency [1] Financial Performance - The company achieved a revenue of 38.205 billion yuan, representing a year-on-year growth of 40.4% [1] - The net profit attributable to shareholders was approximately 1.422 billion yuan, marking a turnaround from previous losses [1] Growth Drivers - The revenue increase was primarily attributed to the sales growth of Baiyueze, licensed products from Amgen, and Baizean [1] - Profitability improvements were supported by revenue growth and enhanced operational efficiency through effective cost management [1]